Navigation Links
Researchers identify a novel therapeutic approach for liver cancer

BOSTON Cancer of the liver rare in the United States but the third-leading cause of cancer death worldwide can result from environmental exposures or infections like chronic hepatitis, but the link is poorly understood.

Now, researchers at Dana-Farber Cancer Institute have identified a mechanism in mice that triggers inflammation in the liver and transforms normal cells into cancerous ones. In addition, they demonstrated in a mouse model that a particular micro-RNA (miR-124) - a member of a recently discovered class of molecular regulators could be harnessed to treat or even prevent liver cancer.

"In this study we are describing for the first time a micro-RNA that is able to prevent and treat liver cancer," said Dimitrios Iliopoulos, of Dana-Farber's Department of Cancer Immunology and AIDS. The findings are being published today in the journal Cell.

The authors said they plan to start a phase I clinical trial using miR-124 in liver cancer patients in 2012.

Iliopoulos and his colleagues found that in mice given a carcinogenic chemical, DEN, liver cancer is initiated by the activation of a molecular circuit that sets up an inflammatory state in the cells, leading to cancer. Once this inflammatory circuit is turned on even for a few days, it becomes permanent, sustaining its activity through a never-ending feedback loop a "snowball effect," as Iliopoulos termed it.

Iliopoulos previously identified a similar feedback circuit implicated in the development of breast cancer.

One element of the circuit is a micro-RNA called miR-124, the Dana-Farber team reported.

Micro-RNAs are extremely short lengths of RNA a messenger molecule that helps the cell build proteins according to DNA instructions - which are not translated into proteins. MiRNAs have been recently implicated in the pathogenesis of human diseases including different types of cancer. The Dana-Farber team found that miR-124 and another key controller of the feedback circuit, HNF4α, showed reduced activity in the cancer cells.

HFN4α is an essential factor in formation of liver cells and their proper function. When HNF4α is suppressed, said Iliopoulos, it creates a temporary state of inflammation in the cell a forerunner of cancer. "After only a few days, this transient inflammatory response is converted into a chronic inflammatory response by this feedback circuit that is continuously amplified," he said.

Because HNF4α and miR-124 interact with each other, the scientists hypothesized that boosting activity of miR-124 might restore normal activity in HNF4α, halting the runaway inflammatory cycle and causing tumors to stop growing.

To test this notion they administered systemically miR-124 once a week for four weeks to mice that had developed liver cancer by exposure to DEN. "We found that miR-124 suppressed more than 80 per cent of tumor growth and size" by causing the cancer cells to self-destruct, the scientists wrote. They observed no toxic effects in other essential organs, such as the kidneys, spleen, heart and lungs.

Further, they showed that giving miR-124 to mice exposed to DEN actually prevented the development of liver tumors.

"Our hope is that miR-124 potentially could be used as a preventive in patients at high risk of liver cancer because they have chronic hepatitis C or as a therapeutic agent in patients with liver cancer" said Iliopoulos.

Contact: Teresa Herbert
Dana-Farber Cancer Institute

Related medicine news :

1. Researchers design Alzheimers antibodies
2. Toronto researchers obtain detailed molecular signature for Tankyrase
3. Danish mushroom inspires cancer researchers
4. Bone Drugs May Also Battle Breast Cancer, Researchers Say
5. Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail
6. UCLA researchers suggest unconventional approach to control HIV epidemics
7. Mayo Clinic researchers find drug duo kills chemotherapy-resistant ovarian cancer cells
8. Researchers discover patterns of genes associated with timing of breast cancer recurrences
9. University of Kentucky researchers awarded CDC grant to study cancer survival in Appalachia
10. Moffitt researchers will be strong participants in American Society of Hematology meeting
11. Moffitt Cancer Center researchers find MK1775 active against sarcomas
Post Your Comments:
Related Image:
Researchers identify a novel therapeutic approach for liver cancer
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... 2016 The Biotechnology industry might ... present great opportunities to investors. assesses the recent ... (NYSE: XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... receive your complimentary trade alerts at: ...
Breaking Medicine Technology: